Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

39.30
Delayed Data
As of Jan 17
 +0.08 / +0.20%
Today’s Change
37.20
Today|||52-Week Range
45.58
+2.05%
Year-to-Date
Flood of News Presents Buying Opportunity
Jan 17 / GuruFocus News - Paid Partner Content
3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock
Jan 10 / MotleyFool.com - Paid Partner Content
Is GlaxoSmithKline's Stock a Bargain After Dropping 4.8% in 2016?
Jan 13 / MotleyFool.com - Paid Partner Content
Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study
Jan 09 / Zacks.com - Paid Partner Content
4 Signs Glaxo's Turnaround Is Taking Hold
Jan 13 / MotleyFool.com - Paid Partner Content
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
Jan 06 / Zacks.com - Paid Partner Content
Hoertkorn Richard Charles Buys Citigroup Inc, GlaxoSmithKline PLC, Wells Fargo & Co, ...
Jan 11 / GuruFocus News - Paid Partner Content
The Best Thing About Glaxo's Next Vaccine (Hint: It's Not the Billion-Dollar Sales Es...
Jan 06 / MotleyFool.com - Paid Partner Content
Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer
Jan 11 / Zacks.com - Paid Partner Content
4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
Jan 04 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close39.22
Today’s open39.24
Day’s range38.94 - 39.37
Volume3,998,771
Average volume (3 months)3,623,416
Market cap$96.3B
Dividend yield5.31%
Data as of 4:02pm ET, 01/17/2017

Growth & Valuation

Earnings growth (last year)+181.82%
Earnings growth (this year)+11.13%
Earnings growth (next 5 years)+13.26%
Revenue growth (last year)-3.66%
P/E ratio350.9
Price/Sales2.70
Price/Book12.59

Competitors

 Today’s
change
Today’s
% change
BMYBristol-Myers Squibb+0.06+0.11%
ABBVAbbVie-0.13-0.21%
CELGCelgene-2.53-2.15%
SNYSanofi-0.51-1.23%
Data as of 4:14pm ET, 01/17/2017

Financials

Next reporting dateFebruary 8, 2017
EPS forecast (this quarter)$0.57
Annual revenue (last year)$36.5B
Annual profit (last year)$12.8B
Net profit margin35.20%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Andrew Philip Witty
Chief Financial Officer &
Executive Director
Simon Dingemans
Corporate headquarters
Brentford, Greater London

Forecasts


Search for Jobs